Identification and treatment of T2-low asthma in the era of biologics
Currently, and based on the development of relevant biologic therapies, T2-high is the most well-defined endotype of asthma. Although much progress has been made in elucidating T2-high inflammation pathways, no specific clinically applicable biomarkers for T2-low asthma have been identified. The the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2021-06-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/7/2/00309-2020.full |